493136_sm9.docx (97.27 kB)View fileThis item contains files with download restrictions
DOCUMENT
493136_sm6.docx (78.64 kB)View fileThis item contains files with download restrictions
DOCUMENT
493136_sm7.docx (89.13 kB)View fileThis item contains files with download restrictions
DOCUMENT
493136_sm8.docx (49.99 kB)View fileThis item contains files with download restrictions
IMAGE
493136_sm1.tif (105.59 kB)View fileThis item contains files with download restrictions
IMAGE
493136_sm5.tif (229.54 kB)View fileThis item contains files with download restrictions
IMAGE
493136_sm3.tif (259.63 kB)View fileThis item contains files with download restrictions
IMAGE
493136_sm4.tif (237.23 kB)View fileThis item contains files with download restrictions
DOCUMENT
493136_sm10.docx (121.41 kB)View fileThis item contains files with download restrictions
Next page
Previous page
1/1
Switch ViewSwitch between different file views
Thumbnail viewList viewFile view
10 filesFullscreen
Supplementary Material for: The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma
posted on 2018-10-03, 08:22authored byopdenWinkel M., Nagel D., opdenWinkel P., Paprottka P.M., Schmidt L., Bourhis H., Trojan J., Goeller M., Reiter F.P., Stecher S.-S., DeToni E.N., Gerbes A.L., Kolligs F.T.
Background/Aims: The recently proposed Munich-transarterial chemoembolisation-score (M-TACE) was tailored to suit hepatocellular Carcinoma (HCC) patients evaluated for TACE. M-TACE outperformed the established HCC-staging-systems and successfully passed external validation. Modifications of staging-systems through the rearrangement of stages or by adding prognostic factors are methods of improving prognostic power. M-TACEs performance compared to scores modified this way should be tested. Methods: Seven well-known HCC staging-systems (including Cancer of the Liver Italian Program-score [CLIP] and Barcelona Clinic liver cancer [BCLC]) and 2 TACE-specific scores (Selection for Transarterial Chemoembolisation Treatment [STATE] and Hepatoma Arterial embolisation Prognostic [HAP]) were rearranged in a cohort of 186 TACE-patients through score-point-analysis and subsequent linking of non-significant adjacent score-points. Additionally, a new score was constructed by combining the top established staging-system in TACE patients (CLIP-TACE) and the prognostic parameter with the highest hazard ratio for death in the TACE-cohort [C-reactive protein (CRP)]. Additionally, the TACE-tailored-scores were applied to an external TACE-cohort (n = 71). Results: Rearrangement resulted in optimal stratification and monotonicity. CLIP-TACE demonstrated the best prognostic capability of all rearranged scores (c-index 0.668, AIC 1294) and the addition of CRP yielded further prognostic improvement (c-index 0.680, AIC 1289). However, superiority over M-TACE could not be achieved by any of the new scores in the internal and external cohort. Conclusion: M-TACE outperforms TACE-tailored modifications of all relevant HCC-staging-systems. Prospective validation of M-TACE to promote its role as the preferred staging-system for TACE-patients is therefore justified.